Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)

Inclusion Criteria: * Newly diagnosed adult patients = 65 years old with a cytopathologically confirmed diagnosis of high-risk AML * = 20% bone marrow blasts via bone marrow aspiration or biopsy * The patient has not yet been treated for AML * 1º or 2º AML patients with high-risk category features * ECOG PS = 2 * Renal function and liver function limits. Exclusion Criteria: * Patient with a 'favorable' or 'better-risk' cytogenetic profile = t(15;17); t(8;21); or inv(16) or t(16;16) * Patient has clinical symptoms suggestive of CNS leukemia and/or CSF findings for CNS leukemia * Prior treatment with deacetylase inhibitors (DACi) including, panobinostat * Impaired cardiac function * Female patient who is pregnant or breast feeding * Male patient who is not willing to use a barrier method of contraception Other protocol-defined inclusion/exclusion criteria may apply